^
Association details:
| Biomarker: | AR mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | onvansertib (PCM-075) (PLK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance -- Trial on track to meet prespecified criteria for success on its primary endpoint, with 31% (8/2
Published date:
10/20/2020
Excerpt:
Cardiff Oncology, Inc....today announced...data and analyses related to its ongoing Phase 2 trial of onvansertib in metastatic castration-resistant prostate cancer (mCRPC) patients...Of 8 patients harboring AR alterations associated with Zytiga® resistance, 3 achieved disease control at 12 weeks, 4 had SD at 12 weeks and 3 had durable SD (>7 months).
Trial ID:
